Articles Tagged: nhs

2 articles found

England & Wales to Offer Free Chickenpox Vaccine from Jan 2026 — What Parents, Schools and Clinicians Need to Know

England and Wales will introduce a free universal childhood varicella (chickenpox) vaccination programme beginning January 2026. This policy aligns the UK more closely with countries that have already reported substantial reductions in varicella incidence, hospitalizations and school outbreaks following universal childhood vaccination. Policymakers have weighed expected gains against long-discussed concerns about potential medium-term changes in herpes zoster (HZ, shingles) epidemiology due to reduced “exogenous boosting” of adult immunity. Dynamic modeling tailored to England and Wales projects large, durable reductions in varicella burden with universal vaccination, with only a modest, temporary uptick in HZ that later falls below baseline as vaccinated cohorts age. Real-world evidence from the United States and European regions adopting two-dose schedules corroborates strong public health impact with significant cuts in primary care visits, hospitalizations, and outbreaks, particularly in school settings. Clinicians, schools, and parents should prepare for updated vaccination schedules, catch-up pathways, documentation requirements, and pragmatic infection control as the programme rolls out. This brief synthesizes the clinical background of varicella-zoster virus (VZV), outlines diagnostic and management considerations, summarizes the evidence base for one- and two-dose strategies, and highlights surveillance priorities and operational implications for the NHS, schools, and families. It integrates UK-focused modeling, comparative international experience, and up-to-date surveillance and clinical trial signals.

varicellachickenpoxVZV+20 more

UK Discounts Mounjaro: What the Price Rebate Means for Patients, the NHS and the Global Weight‑Loss Drug Market

The UK’s confidential discounting of tirzepatide (marketed as Mounjaro for type 2 diabetes and as Zepbound for obesity in some jurisdictions) marks a pivotal moment for metabolic therapeutics. Incretin-based agents—particularly dual GIP/GLP‑1 receptor agonists—have demonstrated substantial and durable weight loss along with metabolic disease modification in large randomized trials. The clinical promise now intersects with health‑system realities: affordability, capacity to scale, and equitable access. For the NHS, price concessions via patient access schemes (PAS) and other commercial arrangements are a well‑established lever to align cost with value. Because obesity imposes rising burdens in cardiometabolic conditions, liver disease, sleep‑disordered breathing, and musculoskeletal morbidity, an effective therapy with long‑term benefits could shift population risk trajectories—if sustained access is feasible. Globally, a UK rebate can reverberate across pricing references, competitor strategies (e.g., GLP‑1 monotherapy), and supply planning, potentially accelerating adoption while intensifying scrutiny of outcomes and budget impact. Concurrent clinical developments—including completed Phase 3 trials in obstructive sleep apnoea (OSA) and ongoing studies on lean‑mass preservation during pharmacologic weight loss—underscore how broader health gains may further strengthen the value case.

tirzepatideMounjaroZepbound+15 more